ArticleThyroid : official journal of the American Thyroid Association2018
Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
Article in Thyroid : official journal of the American Thyroid Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Unveiling a new SORBS2::BRAF fusion in papillary thyroid carcinoma: insights from molecular diagnostics.Virchows Archiv : an international journal of pathology · 2026Article
- A novel signature predicts prognosis in pancreatic cancer based on tumor membrane-associated genes.Heliyon · 2025Article
- LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma.Cell death and differentiation · 2025Article
- Development and validation of disulfidptosis-related genes signature for patients with glioma.Discover oncology · 2024Article
- Role of LMO7 in cancer (Review).Oncology reports · 2024Review
- Immunoreactivity of LMO7 and other molecular markers as potential prognostic factors in oropharyngeal squamous cell carcinoma.BMC oral health · 2024Article
- Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations.European thyroid journal · 2024Article
- Integrated analysis of colorectal cancer metastasis identifies characteristics of tumor cell during metastasis.Gastroenterology report · 2024Article
- Review
- Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.Molecules (Basel, Switzerland) · 2023Review
- Lmo7 recruits myosin II heavy chain to regulate actomyosin contractility and apical domain size in Xenopus ectoderm.Development (Cambridge, England) · 2022Article
- A genome-wide gene-based gene-environment interaction study of breast cancer in more than 90,000 women.Cancer research communications · 2022Article
- LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report.Frontiers in oncology · 2022Article
- Development of an RNA sequencing panel to detect gene fusions in thyroid cancer.Genomics & informatics · 2021Article
- Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.Journal of cellular and molecular medicine · 2021Review
- Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer.Cancers · 2021Article
- Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.Journal of cancer research and clinical oncology · 2021Review
- Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma.International journal of biological sciences · 2021Article
- LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis.Frontiers in cell and developmental biology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe BRAF
methodsGene fusions were analyzed in RNA sequencing data obtained from 12 PTC tumors and paired unaffected thyroid tissue samples. Candidate fusions were further filtered and validated using reverse transcriptase polymerase chain reaction, Sanger sequencing, and fluorescence in situ hybridization. An Ohio cohort of 148 PTC tumor samples was screened for a LMO7-BRAF fusion and the BRAF
resultsTwo coding fusions (CCDC6-RET and LMO7-BRAF) were found in one tumor sample each. The novel LMO7-BRAF fusion was validated by reverse transcriptase polymerase chain reaction and fluorescence in situ hybridization. The LMO7-BRAF fusion was a recurrent somatic alteration with a frequency of 2.0% (3/148) in PTC tumors, while the BRAF
conclusionsA novel fusion gene, LMO7-BRAF, was identified in PTC tumors. The results indicate that the LMO7-BRAF fusion behaves as an oncogenic alteration. This observation expands the spectrum of fusion genes involving kinases in thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.